143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial

Browse by...

Deposit

Highlights

More informations

Title		143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial
Authors		Gautschi, Oliver Li, Q Matter-Walstra, K Betticher, D Frueh, M Rauch, D Pless, M Froesch, P Mach, Nicolas Ochsenbein, A show all authors [1 - 10]
Published in		Journal of thoracic oncology. 2016, vol. 11, no. 4 Suppl, S120
Identifiers		DOI: 10.1016/S1556-0864(16)30253-2 PMID: 27198283
Full text		Article (Published version) (62 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de chirurgie
Research groups		Cancer du poumon et mésothéliome pleural malin (944) Groupe Mach Nicolas (oncologie) (654)
Citation (ISO format)		GAUTSCHI, Oliver et al. 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. In: Journal of thoracic oncology, 2016, vol. 11, n° 4 Suppl, p. S120. doi: 10.1016/S1556-0864(16)30253-2 https://archive-ouverte.unige.ch/unige:93755